
|Articles|April 2, 2007
Latebreakers: Breast cancer agent gets green light
Patients with HER2-positive advanced or metastatic breast cancer whose disease has progressed following treatment with an anthracycline, a taxane, and trastuzumab (Herceptin, Genentech) will now have a new therapeutic option. Lapatinib (Tykerb, GlaxoSmithKline) has been approved by the FDA for use in combination with capecitabine (Xeloda, Roche) following a priority review.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
2
Women Seek Holistic Interventions for Improving Health Outcomes
3
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
4
What TrumpRx Means for Independent Pharmacies and Their Patients
5




























































































































